Andesa Financial Management Inc. acquired a new position in shares of GlaxoSmithKline plc (NYSE:GSK) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,852 shares of the pharmaceutical company’s stock, valued at approximately $246,000.
Other hedge funds have also recently modified their holdings of the company. Wealthcare Advisory Partners LLC grew its position in shares of GlaxoSmithKline by 6.6% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 4,020 shares of the pharmaceutical company’s stock valued at $154,000 after buying an additional 249 shares during the last quarter. 1832 Asset Management L.P. grew its position in shares of GlaxoSmithKline by 35.2% in the 4th quarter. 1832 Asset Management L.P. now owns 967 shares of the pharmaceutical company’s stock valued at $37,000 after buying an additional 252 shares during the last quarter. Reilly Financial Advisors LLC grew its position in shares of GlaxoSmithKline by 36.7% in the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock valued at $36,000 after buying an additional 255 shares during the last quarter. Courier Capital LLC grew its position in shares of GlaxoSmithKline by 3.0% in the 4th quarter. Courier Capital LLC now owns 9,025 shares of the pharmaceutical company’s stock valued at $345,000 after buying an additional 260 shares during the last quarter. Finally, grace capital grew its position in shares of GlaxoSmithKline by 2.7% in the 4th quarter. grace capital now owns 9,833 shares of the pharmaceutical company’s stock valued at $376,000 after buying an additional 263 shares during the last quarter. Institutional investors and hedge funds own 11.10% of the company’s stock.
A number of research firms have commented on GSK. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. Shore Capital lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Exane BNP Paribas lowered GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. BNP Paribas lowered GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. Finally, UBS Group lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Friday, February 22nd. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $41.83.
Shares of NYSE:GSK opened at $40.53 on Tuesday. The stock has a market capitalization of $100.34 billion, a PE ratio of 12.83, a price-to-earnings-growth ratio of 2.04 and a beta of 0.74. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.51 and a current ratio of 0.72. GlaxoSmithKline plc has a 1 year low of $36.41 and a 1 year high of $42.36.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.70 by $0.09. The company had revenue of $10.55 billion for the quarter, compared to the consensus estimate of $9.85 billion. GlaxoSmithKline had a return on equity of 157.04% and a net margin of 12.27%. On average, equities research analysts forecast that GlaxoSmithKline plc will post 2.92 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.89%. The ex-dividend date is Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is 75.32%.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline acquired 325,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were bought at an average cost of $18.00 per share, with a total value of $5,850,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2019/05/07/andesa-financial-management-inc-takes-246000-position-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Investing in Blue-Chip Stocks
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.